Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 25, 2008

TransTech Pharma Acquires Three Programs Related to Metabolic Disorders from Novo Nordisk

  • TransTech gained all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders. This portfolio comprises three distinct therapeutic approaches: H3 receptor antagonists, PPAR-delta agonists, and 11ßHSD1 inhibitors.

    In January 2007, Novo Nordisk decided to divest all its small molecule projects and concentrate on its protein-based pharmaceutical business.

    With this acquisition, TransTech is engaged in 11 clinical and preclinical programs within diabetes and obesity. The other candidates in the company’s portfolio include novel, orally administered compounds targeting PTP1b inhibitors, AgRP inhibitors, GLP1R agonists, AMPK activators, and glucokinase activators.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »